Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Akebia Strikes $350m+ Asian Vadadustat Alliance

This article was originally published in PharmAsia News

Executive Summary

Mitsubishi Tanabe's agreement to acquire selected Asian rights to Akebia's vadadustat will boost the Japanese firm's existing presence in kidney disease while providing important funding for the US company's planned Phase III program with the novel anemia drug.


Related Content

Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh


Related Companies

Related Deals